统一PROMISE PSMA评分:基于68Ga-PSMA-11与18F-DCFPyL参考值校正18F-PSMA-1007肝脏摄取的简易方法
本研究回顾性分析331例PSMA PET-CT(68Ga-PSMA-11、18F-PSMA-1007、18F-DCFPyL),发现18F-PSMA-1007肝SUV显著高于另两种示踪剂,导致PROMISE评分分布失衡;脾脏参考价值有限,而按平均肝SUV倒数比(0.56,95%CI 0.51-0.61)线性校正肝SUV可 harmonize 评分分布。
要点
- 18F-PSMA-1007肝SUV(13.95±4.71)显著高于68Ga-PSMA-11(7.45±4.59)和18F-DCFPyL(8.11±1.78),p<0.01。
- 脾脏SUV与肝SUV仅中度相关(r=0.43),29%病例脾SUV超过肝SUV,不宜作为稳定替代参考。
- 肝SUV乘以0.56校正后,38.2%的score-1病灶被重新分类为score-2,评分分布趋于一致。
核心结论
- 在18F-PSMA-1007 PET中,基于未校正肝或脾摄取的PROMISE评分系统性低估病灶评分。
- 简单的线性校正方法(肝SUV×0.56)为提高PSMA评分一致性提供了研究路径。
研究设计与样本
- 回顾性分析331例连续PSMA PET-CT研究,68Ga-PSMA-11、18F-PSMA-1007、18F-DCFPyL分别为118、95、118例。
- 在所有研究中测量血池、肝脏、腮腺SUV,18F-PSMA-1007组另记录脾脏SUV。
- 数据来自前瞻性注册试验(ClinicalTrials.gov NCT03718260,2018年10月24日注册)。
主要发现
- 肝SUV:18F-PSMA-1007(13.95±4.71)> 68Ga-PSMA-11(7.45±4.59)≈ 18F-DCFPyL(8.11±1.78),p<0.01。
- 18F-PSMA-1007肝摄取升高扩大了score-1的SUV范围(血池至肝脏),压缩了score-2范围(肝脏至腮腺)。
- 18F-PSMA-1007组脾SUV为12.24±5.67,与肝SUV仅中度相关(r=0.43),29%病例脾SUV超过肝SUV。
- 线性校正因子为0.56(95%CI 0.51-0.61),校正后18F-PSMA-1007组肝SUV为7.8±2.63。
- 以脾SUV作为score 1-2界值仅将11.8%的score-1病灶升级为score-2,未能解决分布失衡;以校正肝SUV(肝SUV×0.56)为界值则使38.2%的score-1病灶重新分类为score-2。
关键数值与推荐
- PROMISE评分以血池、肝脏、腮腺为参考器官定义SUV范围。
- 18F-PSMA-1007肝SUV线性校正因子=0.56(95%CI 0.51-0.61),即校正肝SUV=原肝SUV×0.56。
- 脾脏SUV作为score 1-2界值仅11.8%病灶升级,校正肝SUV作为界值则38.2%病灶升级。
临床怎么用
- 对18F-PSMA-1007 PET解读时,需注意未校正肝摄取会系统性低估PROMISE评分。
- 可考虑采用肝SUV×0.56的校正值作为score 1-2界值,以改善与肾排泄示踪剂的评分一致性。
- 脾脏摄取不宜作为肝摄取的稳定替代参考。
局限性
- 脾脏参考未经过定量验证。
- 线性校正方法仅为研究路径,尚需进一步验证。
- 本研究为回顾性分析,校正因子基于平均肝SUV比值推导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PROMISE framework standardizes PSMA PET interpretation using reference organs, particularly the liver. For hepatobiliary-excreted tracers (e.g., 18F-PSMA-1007), the spleen was proposed as an alternative reference, though without quantitative validation. We evaluated PSMA-ligand uptake patterns among 18F-PSMA-1007, 68Ga-PSMA-11, and 18F-DCFPyL to assess the validity of spleen-based referencing and develop a simple approach that may harmonize 18F-PSMA-1007 liver uptake with that of renally-excreted tracers. RESULTS: 331 consecutive PSMA PET-CT studies (n = 118/95/118 for 68Ga-PSMA-11/18F-PSMA-1007/18F-DCFPyL) were analyzed: SUVs were retrospectively measured in all studies in reference tissues (blood pool, liver, parotid), with SUVspleen also recorded for 18F-PSMA-1007. SUVliver differed markedly across tracers: 18F-PSMA-1007 (13.95 ± 4.71) > 68Ga-PSMA-11 (7.45 ± 4.59) ≈ 18F-DCFPyL (8.11 ± 1.78), p < 0.01. The elevated 18F-PSMA-1007 liver uptake expanded the PROMISE score-1 range (SUV range between SUVblood pool and SUVliver) and compressed that of score-2 (SUV range between SUVliver and SUVparotid). SUVspleen in this group (12.24 ± 5.67) showed only moderate correlation with SUVliver (r = 0.43) and exceeded SUVliver in 29% of cases, questioning the utility of spleen uptake as a consistent alternative to liver uptake-based cutoff. Linear correction using the inverse ratio of mean SUVliver (18F-PSMA-1007 versus other tracers; factor = 0.56, 95% CI 0.51-0.61) yielded SUVliver-corrected of 7.8 ± 2.63 in the 18F-PSMA-1007 group. Applying SUVspleen as a PSMA score 1-2 cutoff failed to resolve score distribution imbalance, upstaging only 11.8% of score-1 lesions to score-2. By contrast, the use of SUVliver-corrected (SUVliver × 0.56) as this cutoff harmonized the score distribution in the 18F-PSMA-1007 cohort relative to 68Ga-PSMA-11 and 18F-DCFPyL, leading to reclassification of 38.2% of score-1 lesions as score-2. CONCLUSION: In PET with 18F-PSMA-1007, PROMISE scoring based on unadjusted liver or spleen uptake systematically underestimates lesion scores. The simple linear correction approach proposed here offers a research avenue for enhancing the consistency of PSMA scoring for improved interpretive standardization. This study contains data obtained from a prospective Registry Trial: ClinicalTrials.gov, NCT03718260, registered October 24, 2018.
引用
- Anconina R, Priss M, Landau E, et al. Toward harmonized PROMISE PSMA scoring: a simple approach for correcting 18F-PSMA-1007 liver uptake based on 68Ga-PSMA-11 and 18F-DCFPyL reference values. EJNMMI Res. 2026. PMID: 42902110. doi:10.1186/s13550-026-01499-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。